IDEXX Laboratories Q2 Earnings Call Highlights

3 weeks ago 6

MarketBeat

Tue, August 4, 2026 astatine 11:04 AM CDT 6 min read

Key Points

Interested successful IDEXX Laboratories, Inc.? Here are 5 stocks we similar better.
IDEXX reported beardown Q2 performance, with gross up astir 10% reported and 9% organically, portion EPS roseate 18% to $4.27. Companion carnal diagnostics recurring gross grew 10.3% organically contempt a 1.3% diminution successful U.S. same-store objective visits.
The company's merchandise pipeline continued to summation traction: IDEXX placed 1,602 inVue Dx analyzers during the 4th and remains connected way for 5,500 placements successful 2026, portion Cancer Dx surpassed 10,000 ordering clinics and FNA investigating is acceptable for broader rollout by year-end.
IDEXX raised its 2026 outlook, projecting gross of $4.70 cardinal to $4.745 billion, comparable EPS of $14.69 to $14.94, and free-cash-flow conversion of 90% to 100% of nett income. Strong margins, currency travel and stock repurchases supported the improved forecast.

These 3 Water ETFs Could beryllium Quiet Winners From Infrastructure Spending

IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter 2026 gross maturation of astir 10% connected a reported ground and 9% organically, driven by companion carnal diagnostics, h2o and livestock, poultry and dairy businesses. The institution raised its full-year gross and net outlook, citing beardown recurring diagnostics revenue, product-cost benefits and continued momentum from caller merchandise introductions.

Chief Financial Officer Andrew Emerson said second-quarter gross maturation was supported by much than 10% integrated maturation successful companion carnal group, oregon CAG, Diagnostics recurring revenue. The institution generated net per stock of $4.27, up 18% arsenic reported and 15% connected a comparable basis.

Diagnostics Growth Outpaces Clinical Visits

→ SpaceX's First Earnings Report Could Decide Whether Shorts oregon Bulls Have Control

Bullish oregon Bearish? Vetting Animal Health Care Stocks

CAG Diagnostics recurring gross roseate 10.3% organically successful the 2nd quarter, including astir 4% planetary nett terms betterment and a 50-basis-point antagonistic interaction from equivalent days. U.S. CAG Diagnostics recurring gross accrued astir 10%, portion planetary recurring gross grew astir 12% organically.

The maturation came contempt an estimated 1.3% diminution successful U.S. same-store objective visits. Emerson said IDEXX achieved an astir 1,100-basis-point maturation premium successful U.S. CAG Diagnostics recurring gross comparative to objective visits.

→ Financials Hit Record Highs arsenic the AI Trade Unravels—Can They Keep Leading?

The institution said unit connected wellness visits remained the superior origin constraining wide objective visits, portion non-wellness visits posted humble growth. CEO Mike Erickson said pets ages 5 and older continued to lend affirmative maturation successful some wellness and non-wellness visits, a inclination the institution has observed for aggregate quarters.

Read Entire Article